Black Diamond Therapeutics (BDTX) Common Equity (2018 - 2021)
Historic Common Equity for Black Diamond Therapeutics (BDTX) over the last 4 years, with Q3 2021 value amounting to $218.9 million.
- Black Diamond Therapeutics' Common Equity fell 3311.4% to $218.9 million in Q3 2021 from the same period last year, while for Sep 2021 it was $218.9 million, marking a year-over-year decrease of 3311.4%. This contributed to the annual value of $307.8 million for FY2020, which is 75262.42% up from last year.
- According to the latest figures from Q3 2021, Black Diamond Therapeutics' Common Equity is $218.9 million, which was down 3311.4% from $251.0 million recorded in Q2 2021.
- In the past 5 years, Black Diamond Therapeutics' Common Equity ranged from a high of $355.3 million in Q1 2020 and a low of -$47.2 million during Q4 2019
- Moreover, its 4-year median value for Common Equity was $235.0 million (2021), whereas its average is $160.9 million.
- Its Common Equity has fluctuated over the past 5 years, first plummeted by 20341.65% in 2019, then surged by 194275.64% in 2020.
- Quarter analysis of 4 years shows Black Diamond Therapeutics' Common Equity stood at -$15.5 million in 2018, then crashed by 203.42% to -$47.2 million in 2019, then skyrocketed by 752.62% to $307.8 million in 2020, then decreased by 28.86% to $218.9 million in 2021.
- Its Common Equity was $218.9 million in Q3 2021, compared to $251.0 million in Q2 2021 and $280.8 million in Q1 2021.